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2SUMMARY
It is essential for the integrity of double-blind clinical trials that during the study course
the individual treatment allocations of the patients as well as the treatment effect remain
unknown to any involved person. Recently, methods have been proposed for which it
was claimed that they would allow reliable estimation of the treatment effect based on
blinded data by using information about the block length of the randomisation
procedure. If this would hold true, it would be difficult to preserve blindness without
taking further measures. The suggested procedures apply to continuous data and their
characteristics were illustrated by applying them to a single simulated data set per
scenario considered. We investigate the properties of these methods more thoroughly by
repeated simulations per scenario. Furthermore, a method for blinded treatment effect
estimation in case of binary data is proposed, and blinded tests for treatment group
differences are developed both for continuous and binary data. We report results of
comprehensive simulation studies that investigate the features of these procedures. It is
shown that for sample sizes and treatment effects which are typical in clinical trials, no
reliable inference can be made on the treatment group difference which is due to the
bias and imprecision of the blinded estimates.
KEY WORDS: clinical trial; blindness; treatment effect; block randomisation; trial
integrity.
31. INTRODUCTION
One of the most important issues in the design of clinical trials is the implementation of
procedures that eliminate or minimise bias. Blinding and randomisation are generally
considered to be the most important techniques in this context  1 . While randomisation
eliminates bias in treatment assignment, blinding minimises the risk of trial personnel or
patients being aware of the assigned intervention and thus from being influenced by
this. Knowledge of treatment group assignment may, beside others, affect the response
of the participants, influence the use of ancillary interventions of the investigators, or
lead to a differential judgment of the outcome by the assessors  2 . But even if
individual treatment assignments are unknown, knowledge of the size of the treatment
effect during an ongoing trial may influence the attitude of anyone involved in the trial
and may thus lead to the occurrence of bias by mechanisms as such described above.
For this reason, regulatory guidelines strongly demand that the results of interim
analyses are not disseminated to the personnel and patients involved in a trial  1, 3 . It is
therefore standard that any comparison between treatment groups that is performed mid-
course of a trial is assigned to an independent committee which maintains the results
strictly confidentially  4 . The only information that is disseminated beyond the small
circle of committee members is whether the trial was stopped or continued. As a further
measure, information on who is assigned to which treatment group is not included in the
trial database while the study is ongoing but is kept separately with special access
rights.
Usually, general information on the implemented randomisation procedure is given
in the protocol, such as the method used for random sequence generation or prognostic
4variables that are taken into account in stratified randomisation. Quite frequently, block
randomisation is applied to minimise the risk of obtaining an undesirable sample size
imbalance between the treatment groups. In order to prevent from the possibility of
predicting the assignment of future patients from guessed or known assignments of
patients already allocated, it is recommended not to specify the block length in the
protocol  5 . However, trial statisticians are generally aware of the block lengths and -
as they have access to the trial database - they also know the order in which the patients
were recruited. Therefore, they are aware of which patients are in which block. It is
evident that for extreme outcome scenarios this knowledge can be used to derive
information about the treatment effect even if the individual treatment group allocation
remains blinded. For example, in the case of a binary endpoint “event yes / no” where in
every block either the event occurs for all patients or does not occur for any patient, it is
clear that there is no difference in treatment effect between the groups. The question
arises, whether reliable conclusions about the treatment effect can be drawn from the
blinded data also in more realistic situations. The message given in a recent paper by
van der Meulen  6 raises hopes or fears - depending on the perspective - that this
would be possible. In the abstract of [6] it was claimed that when randomisation is done
using permuted blocks “statistical inference of the treatment effects can be conducted”
before unblinding “yielding consistent and rather precise estimates“  6, . 479p . In the
light of the above-mentioned fact that the integrity of the trial is questioned if
information about the extent of the treatment effect becomes known and if actions are
taken based on this information during the course of a trial, this would create serious
problems.
5Other methods that allow a blinded estimation of the treatment effect have been
proposed in the literature before. In the framework of blinded sample size re-estimation,
Gould and Shih [7] suggested a method to estimate the within-group variance of
normally distributed data. This procedure is based on an EM algorithm and does not
make use of information about the randomisation. It provides not only an estimate of the
within-group variance but also of the treatment effect. It was shown that this approach
exhibits some major deficits and is not appropriate for sample size re-estimation based
on the blinded variance estimate [8, 9]. Waksmann [10] corrected the Gould-Shih
procedure such that now the resulting estimates converge to the ML estimates. He
investigated the characteristics of the resolved method in a thorough simulation study
and found that for sample sizes and treatment effects that usually occur in clinical trials,
the estimates of the treatment group difference are not accurate enough to be of practical
value. The same conclusion was drawn by Xing and Ganju [11] for the procedure they
derived by making use of the knowledge of the randomisation block length. Their
primary focus was the construction of a blinded variance estimator for the purpose of
blinded sample size re-estimation in case of continuous data. They briefly mention that
a blinded estimator of the treatment effect can be obtained as a by-product, based on the
difference between the pooled one-sample variance estimator for all data and their
blinded within-group variance estimator (which is a multiple of the variance of the
block means). Based on heuristic arguments and simulation results, Xing and Ganju
concluded that “there is no risk of unblinding the trial” because “the variation in the
estimate of 2 is large enough to be practically useless”. In contrast to the other
references mentioned above, van der Meulen [6] focuses on estimation of the treatment
effect using estimators based on all available effect information in the blinded data.
6Interestingly, he derived blinded moment and ML estimators of the treatment group
difference for continuous data that use the knowledge of the block length applied in
randomisation. His work on the estimators is therefore a good basis to investigate the
amount of effect-information contained in blinded data. Besides, van der Meulen’s [6]
investigations suggest that the blinded estimates of the variance he derived with the ML
method are more precise than the blinded treatment effect estimates. Recently, Ganju
and Xing [12] discussed specifically the blinded treatment effect estimation of van der
Meulen and concluded that “the blinded method is refined enough for blinded variance
estimation but blunt enough for inferring efficacy”.
The aim of our paper is to assess the risk of unblinding the treatment effect from
blinded inference. This goal is examined (i) by investigating the procedure proposed by
van der Meulen for continuous data more thoroughly by simulation studies; (ii) by
developing alternative approaches for a blinded assessment of treatment effects by
utilising knowledge of the randomisation block length in case of continuous and binary
outcomes; and (iii) by investigating comprehensively the characteristics of the new
methods. Thereby, previous work on blinded estimation of treatment group differences
is extended in various ways. Section 2.1 takes a closer look to the characteristics of the
procedure proposed by van der Meulen for blinded estimation of treatment effects in
case of continuous data by presenting results of repeated simulations. In Section 2.2, a
blinded test for difference of means is derived and its properties are investigated. An
example illustrates the findings in Section 3. Related methods for binary data did not
exist up to now. Section 4 presents blinded estimators of and a test for treatment group
difference in case of binary outcomes and shows their characteristics. We summarise
the findings in Section 5 and discuss them in the context of the literature.
72. BLINDED ASSESSMENT OF TREATMENT EFFECT FOR
CONTINUOUS DATA
2.1 Blinded estimation of treatment effect
Here and in the remainder of the paper the treatment effect, i.e., the difference of the
expected values in the two intervention groups, is denoted by  . Hence, in case of
continuous data 21   with group expectations 1 2,  . We start with a block
length of 2l  and adopt the notation used in Reference  6 . Let 1 2,i iY Y denote the 1
st
and 2nd observation in block i, ki ...,,1 , where 2)var( ijY , ki ...,,1 , 2,1j .
Further, 211 iii YYZ  is the within-block difference in block i and 212 iii YYZ  the
within-block sum in block i, ;...,,1 ki  22iZ is therefore the mean in block i. The
between-block variation (i.e., the variance of block means) can thus be expressed as
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Consequently, an unbiased estimator of 2 is given by 22 42 BBWB SS  , and the absolute
value  of  can be estimated by  0,42max 22 BBWB SS  . This is the moment
estimator  of  presented in  6 . No assumptions are to be made regarding the
distribution of the observations when deriving this estimator. Alternatively, the
8maximum likelihood (ML) estimator  of  can be derived under the assumption
of normally distributed observations ijY . The log likelihood is then given by
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where ),;( 2 y is the density of a normal distribution with mean  and variance
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  6 . The ML estimates can be obtained by maximising the log likelihood using the
Newton-Raphson algorithm, as for example implemented in the SAS/IML function
nlpnra. The moment estimators for  , 1 2
1 ( )
2
    and 2 can be used to
initialise the algorithm. Analogously, the moment estimator and the ML estimator of
 can be derived for a block length of 4l  (see  6, . 483p ff and Appendix A for a
correction of the moment estimator given in [6]).
Figures 1 and 2 show the simulated bias    of the moment estimator and the
ML estimator  for  for block lengths of 2l  and 4l  , respectively. Considered
were (standardised) treatment effects 5.0,25.0,0 and 1.0 ( 1 ) and total sample
sizes 20, 40, …, 100, 200, …, 800, 1,000 which were balanced between the two groups.
It should be noted that total sample sizes of 506, 128 and 34 are required to achieve a
power of 80 per cent at one-sided level 0.025  with the unblinded t-test for
standardised differences of 0.25, 0.5  and 1.0 , respectively. For each situation,
1,000 simulations were performed.
– Please insert Figures 1 and 2 about here. –
Both the moment estimator and the ML estimator overestimate the absolute value of the
treatment effect for 0  and 0.25  for all sample sizes, while underestimation
9occurs for 1  (with the only exception of 4l  and total sample sizes smaller than
40). As could be expected, the extent of bias is for the same sample sizes generally
higher for block size 4l  than for block size 2. For 0.5  , a positive bias is observed
for small sample sizes which changes to a negative bias when the sample size is
increased. The shift from overestimation to underestimation occurs for higher sample
sizes for block size 4l  as compared to 2l  . In all considered situations, the mean
estimates resulting from the moment estimator are slightly smaller than those for the
ML estimator, but the difference is negligible for practical purposes. For 0  , the bias
approaches zero only for sample sizes which would have been used if the relevant effect
assumed at the planning stage was much smaller than the true treatment effect  . As a
reviewer noted, this result is also reflected in Table 1 of van der Meulen’s paper [6]: For
the data set he used, the treatment effect is estimated precisely from blinded data only
when the trial has extremely high power (> 99%); see also [12].
The simulations also show that the standard deviations of the two blinded estimators
are very similar as well. The variability is higher for block size 4l  as compared to
2l  . In comparison to unblinded estimation of the treatment effect, the standard
deviation of the blinded estimates is considerably higher by a factor of up to 3 for the
range of investigated parameter constellations (results not shown).
What do these results mean in terms of information about the treatment effect that
can be inferred from blinded data of an ongoing trial? For example, if a clinical trial is
powered for 1 0.80  at a clinically relevant treatment effect of * 0.25  , this
requires a total sample size of * 506n  (balanced groups, t-test at one-sided level
0.025 ). If block randomisation with a block size 2 is applied and the treatment
effect is estimated by application of the blinded moment or ML estimator based on the
10
data of 500 patients utilising the information 2l  , then Figure 1 shows that the
expected estimated treatment group difference amounts to about 0.27 if the true
treatment effect is in fact 0.25  . However, if there is actually no treatment group
difference at all ( 0  ), the expected blinded estimate is about 0.21. It is therefore
evident that in this situation one is not able to distinguish whether a blinded estimate of,
say, 0.25 arises from overestimation of a non-existing treatment group difference or
from a treatment effect 0  .
– Please insert Figure 3 about here. –
Figure 3 considers this aspect in more detail. The box-whisker plots show for block
lengths 2l  and 4l  the range of the central 90 per cent of values arising from 1,000
simulated blinded treatment effect estimates (moment estimator grey, ML estimator
white). It can be seen that there is a heavy overlap of the distributions of the blinded
estimators that originate from different values of  . Furthermore, with the exception of
the constellations of a total sample size of 500 and 2, 0.75,1l    and 4, 1l    , the
box-whisker plot includes the value zero. Hence, for adequately powered studies a
blinded estimate of zero gives no indication at all about the actual underlying treatment
effect. The other way round, for 0  and 2l  ( 4l  ) the upper whisker reaches the
value 1.25, 1.0, and 0.65 (1.5, 1.25, and 0.85) and total sample sizes of 40, 100, and
500, respectively. This means that only huge treatment effect estimates would give
cause to the suspicion of a non-zero treatment effect. Figure 3 shows that such estimates
occur with considerable probability only for at least as extreme true treatment effects.
As a consequence, for treatment group differences and sample sizes which are common
in clinical trials, a differentiation between various extents of  based on the blinded
moment or ML estimator is not possible. This uncertainty about the actual amount of 
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is a consequence of the substantial positive bias of the blinded estimators for the
situation 0  combined with a high variability of the estimates.
In order to study the sensitivity of our findings to deviations from the normal
distribution we conducted simulations with non-normal distributions including
distributions with heavy tails (t-distributions with small number of degrees of freedom)
and skewed distributions (e.g. log normal distribution). We found that the results for the
moment estimator are robust against such deviations. However, the ML estimator was
sensitive to deviations from normality as expected with at times severe downwards bias
in estimation of the treatment effect Δ. The general observation for non-normal 
distributions was that the performance of the blinded estimators is not better as seen for
normal data. A differentiation between various extents of  based on the blinded
moment or ML estimator is even more difficult.
2.2 Blinded tests for treatment effect
From the above mentioned formulae for the within-block variation and the between-
block variation, a blinded F-test can be derived. As the F-test and the moment estimator
are closely related, it cannot be expected that this test will be more revealing than the
findings presented in Section 2.1, but is an alternative way to look at this problem. For
block length 2l  the test statistics is given by
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blinded F-test can be derived for block length four, which is given in Appendix A.
, 4blind lF  can again be interpreted as the ratio of the within-block variation to the
between-block variation and follows the non-central F-distribution
2
3 , 1 2k k
kF

 
 
 
. Due
to the known distribution of the test statistics, the power properties of the blinded F-tests
can be evaluated analytically.
– Please insert Figure 4 about here. –
Figure 4 shows the relationship between the treatment effect * used for sample size
calculation and the ratio r of the true treatment effect  to the effect * that is
required to achieve a power of 1 0.5  and 0.8 , respectively, for the blinded F-test
with significance level 05.0 . The sample size is chosen such that the unblinded
two-sided t-test at 05.0 has a power of *1 0.8  at the treatment effect
* ( =1)  . This means that r is determined such that
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1 2, ,
Probfdf df  denotes the
distribution function of the non-central F distribution with 1 2( , )df df degrees of freedom
and non-centrality parameter  ,
, ,1 2df df
f

is the  quantile of the central F distribution
with the same degrees of freedom, and z

is the  quantile of the standard normal
distribution.
For 2l  ( 4l  ) and a clinically relevant treatment effect * 0.25  assumed for
sample size calculation, a 2.7 (3.7) times larger true treatment effect  is necessary to
achieve a 50 per cent power for the blinded F-test. A factor of about 3.4 (4.6) between
the actual treatment effect and the effect used for sample size calculation is required to
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have an adequate power of 80 per cent. From another perspective, if * 0.25    the
factor between the chosen and the required sample size amounts to about 46 (136) for a
desired power of 50 per cent of the blinded F-test and to about 104 (309) for 80 per
cent. For a clinically relevant treatment effect of * 0.5  the situation becomes a little
bit less extreme. However, still about double (2.8 times) this treatment effect is
necessary to achieve a power of 50 per cent for the blinded F-test, and the true effect
needs to be about 2.6 (3.7) times as large as this effect to get a power of 80 per cent for
the blinded test. In other words, for * 0.5    the total sample size required to
achieve 80 per cent power for the blinded F-test amounts to about
3,560 ( 10,340)n n  while the chosen sample size is * 128n  .
In practice, one would usually try to learn from the blinded data while the study is
still ongoing. Hence, the blinded test would be applied before the data of all *n patients
are available. As a consequence, the required factors by which the true effect has to
exceed the one used for sample size calculation to achieve a power of 50 or 80 per cent
for the blinded test are even higher as those reported above.
These considerations show that the blinded F-test has reasonable power only when
the true treatment effect is several times larger than the clinically relevant effect
assumed in the sample size calculation of the study, i.e. if the study is an overpowered
study from a retrospective point of view. Though there is a possibility for this to
happen, this is a very rare event in clinical practice.
14
3. EXAMPLE
In order to illustrate the results, we consider placebo-controlled clinical studies in the
acute treatment of major depression. The change in total score of the Hamilton Rating
Scale for Depression (HAM-D, 17-item version)  13 between baseline and end of
therapy is often used as the primary endpoint in such studies, and a difference of * 3 
points can be considered as clinically relevant  14 . If the standard deviation  is
assumed to lie within the range of 5 to 8 as usually observed for this outcome (see, for
example, Reference  15 ). This corresponds to total sample sizes of 90 to 230 required
to achieve a power of 80 per cent for the treatment group difference * 3  (two-sided
t-test, 05.0 ). These sample sizes match well the number of patients typically
included in studies investigating the efficacy of the treatment of acute major depression
(see, for example, the systematic reviews  15,16 ).
The true treatment group difference needed to achieve a power of 1 0.80  for
the blinded F-test would amount to 7.4 ( 5  ) or 8.8 ( 8  ) HAM-D points,
respectively, for block length two and 10.5 ( 5  ) or 11.9 ( 8  ), respectively, for
block length four. For all existing antidepressants, such huge overall treatment effects
are out of reach. The other way round, if the true treatment effect would amount to
3  HAM-D points, the sample size required to attain a power of 1 0.80  for the
blinded F-test would be 1,800 ( 5  ) or 10,700 ( 8  ), respectively, for block length
two, and 5,200 ( 5  ) or 31,500 ( 8  ), respectively, for block length four. However,
there is no reason to perform such large-scale placebo-controlled studies investigating
the efficacy of short-term treatment of major depression.
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In a double-blind, placebo-controlled trial Kalb et al.  17 investigate the efficacy of
St. John’s wort in patients with mild to moderate depression. The primary variable was
the change in HAM-D total score between baseline and end of the six weeks acute
treatment phase. Due to the uncertainty about the variability of the primary endpoint and
the expected treatment effect, the study was planned with an interim analysis that
should be performed when roughly half of the projected sample size of 130 was
achieved. A block length of two was used for randomisation. For those 72 patients that
were included in the interim analysis, 35 blocks were complete such that a blinded
assessment could be based on 70 patients. Applying the blinded ML- and moment
estimator to this data set leads to estimated treatment effects of 3.2 and 2.4 points,
respectively. Employing the one-sample estimator of the standard deviation of 6.3
results in an estimated standardised treatment effect of 0.4 to 0.5. In view of the results
shown in Figure 3, this estimate is compatible with true treatment effects from 0.0 to
1.0. Application of the blinded F-test leads to a test statistic of 1.08F  , which
corresponds to a p-value of 0.42p  . Hence, blinded estimation and testing give no hint
for a significant difference between the two treatment groups. However, the unblinded
estimate of the difference between the group means amounts for the same data set to 5.1
and the two-sample t-test results in a two-sided p-value of 0.0004p  . As a
consequence, the study could be stopped after the planned interim analysis with a
significant superiority of St. John’s wort to placebo (pre-defined critical boundary for
early rejection 1 0.0207  ), whereas the blinded methods would not have given any
indication to complete the trial early. Therefore, this real study data give another
counter-example to the claim that blinded inference “takes away the need of conducting
interim analyses”  6 .
16
4. BLINDED ASSESSMENT OF TREATMENT EFFECT FOR
BINARY DATA
4.1 Blinded estimation of treatment effect
In case of binary data, we consider the ML estimator and the moment estimator for
blinded estimation of the treatment effect. We will see that this approach leads to a
simple expression for the estimator. In order to avoid repetition we restrict the
presentation here to block length 2l  as in this situation most information can be
drawn from the blinded data thus marking the best case scenario for the performance of
blinded estimation methods.
The information included in blinded binary data is the number of events that
occurred in each block and the order they occurred. In the case of block size 2l  , the
numbers 201100 ,,, aaaa of blocks with 0 events, with one event that occurs for the first
patient, with one event that occurs for the second patient and with two events,
respectively, can be observed. If 10a or 01a is “large”, one would become suspicious that
there may be a difference between the treatment groups. In contrast, for every block
with no event or two events one knows for sure that there is no difference between the
number of events between the treatment groups.
The blinded ML estimator for the difference in event rates between the two
treatments can be derived analytically. If ip denotes the true event rate in treatment
group 2,1i , then the probabilities of observing a block with 0, 2, or 1 event are
1 2(1 )(1 ) p p , 1 2p p , and 1 2 1 21 (1 )(1 )   p p p p , respectively. The probabilities to
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observe a block with one event that occurs in the first patient or a block with one event
that occurs in the second patient are equal. Hence, the likelihood function is given by
        
10 010 2
1 2 1 2 1 2 1 21 1 1 1 1 / 2
a aa ap p p p p p p p

          
. We can restrict on
using the total number of blocks with one event 1 10 01 a a a instead of 10 01( , )a a , since
the likelihood function shows that 0 1 2( , , )a a a is a sufficient statistic. If the expression
above is re-parameterised with 2/)( 21 pp  , 2/)( 21 ppq  , and
2qd  , it can
be seen after some calculation that the log likelihood is maximised for
)2/()2(ˆ 21 kaa  (which is the observed overall event rate) and for
2
20
2
1 )2()4(ˆ kaaad  if
2 2
1 0 2( 4 ) (2 ) 0a a a k  , and 0ˆ d otherwise. Hence, the
blinded ML estimator for 1 2= 2p p d   in case of block length 2l  is given by
 2
1 0 2
1 max( 4 , 0)  a a a
k
.
Another possibility is to apply the moment estimator presented in Section 2.1 directly
to binary data. In case of binary data and block length 2l we find )2/(1
2 kaSWB  and
2 2 2 2
0 1 2ˆ ˆ ˆ( ( 0.5) (1 ) ) /( 1)BBS a a a k        . With these expressions, the moment
estimator  0,42max 22 BBWB SS  for 21 pp  can be calculated.
– Please insert Figure 5 about here. –
Figure 5 shows the box-whisker plots covering the central 90 per cent of the empirical
distribution of the blinded estimates for 2l  (moment estimator grey, ML estimator
white) arising from 1,000 simulations for each situation. Overall rates 1 2( ) / 2p p  
of 0.2, 0.5, treatment effects 1 2p p   of 0, 0.05, …, 0.3 and balanced total sample
sizes of 100, 500 and 1000 were considered. Qualitatively, the results are very similar to
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those obtained for continuous data. Again the box-whisker plots show an extensive
overlap for different values of  and  . Moreover, they cover the value zero for almost
all considered situations with the exception of some combinations of a total sample size
of 500 or 1,000 and treatment effects of 0.25 or 0.3. However, in these situation the total
sample size required to achieve a power of 80 per cent with the unblinded chi-square
test is extremely much lower and ranges from 54 ( 0.2, 0.3    ) to 86
( 0.5, 0.3    ). Hence, for reasonably powered studies a blinded estimate of zero for
the treatment group difference is both in accordance with the assumption 0  and
0  . As for continuous data, the upper whiskers reach very large treatment effects for
0  , for example values of 0.50, 0.32, and 0.27 for an overall rate of 5.0 and
total sample sizes of 100, 500, and 1,000, respectively. Therefore, only if even more
extreme values are obtained from blinded estimation of the group difference it is worth
to speculate whether the true treatment effect might be different from zero. However,
such large estimated effects occur in turn only for very large true differences with
noticeable probability. In summary, it can be concluded that for treatment effects and
sample sizes which are usually met in clinical trials different values of  cannot be
distinguished by blinded moment or ML estimation.
4.2 Blinded tests for treatment effect
In Section 2.2 we introduced the F-test
2
, 2 2
WB
blind l
BB
SF
S
 for continuous data that we could
apply for binary data as well. In case of binary data and block length 2l we can
employ the expressions for 2WBS and
2
BBS given in the previous section. Unlike with
normal data, however, the reference distribution is not an F-distribution. One way of
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obtaining a reference distribution is by considering all permutations of ‘1’ (event) and
‘0’ (no event) keeping the total number of events fixed. It can be shown that the
between-block variation 2BBS is invariant to permutations. Therefore, the test statistics
reduces to 1a after elimination of invariants, with larger values of 1a being stronger
evidence against the null hypothesis of no effect. A p-value for the test is given by
1
2
( / 2)
2
1 1
max{0, } 2 1
2 { }
floor e
b
b e k
k k b
b a
b b 
   
    
   
 ,
where ( )floor x is the largest integer that is less than or equal to x, 122 aae  ,
2211 2)( bebbb  , and {}  denotes the indicator function.
– Please insert Figure 6 about here. –
Similar to Figure 4 in Section 2.2, Figure 6 shows the relationship between the risk
difference  used for sample size calculation and the ratio r of the actual risk
difference  to the effect  that is required to achieve a power of 5.01   and 8.0 ,
respectively, for the blinded permutation test given above with an overall event rate of
2.0 and 0.5. Using the approximation formula given in  18 the sample size is
calculated such that the unblinded two-sided Fisher’s exact test has a power of
8.01   for level 05.0 , overall event rate 5.0,2.0 , and difference in event
rates  . The ratios r were determined by means of line searches over  with step size
0.005. Hereby the power values of the blinded test were simulated using 50,000
replications.
As can be seen from Figure 6 the risk differences need to be 2 to 4 times larger than
anticipated in order to obtain a power in the range of 0.5 to 0.8 for the considered
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combinations of rate differences and overall event rates. This is in keeping with similar
effects observed in Figure 4.
Alternative test statistics could be used for the permutation test. For instance, the
MLE of the treatment difference given above or the likelihood ratio test (LRT) statistic
would make good choices. Both statistics lead to tests equivalent to the one used above.
5. DISCUSSION
We saw that it is possible to construct both for continuous and for binary data estimators
and tests for the treatment effect that are based on blinded data by utilising information
about the randomisation procedure. Although we demonstrated this only for block sizes
of 2 and 4, this applies for other block sizes. Not surprisingly, the information that can
be gained from blinded data is highest for the smallest possible block size of 2. But even
in this situation, a reasonable precision for the treatment effect estimate can hardly be
obtained in realistic scenarios. Furthermore, the blinded tests have sufficient power only
if the study is severely overpowered: For a block size of 2, the actual treatment effect
has to exceed the clinically relevant effect by a factor of at least 2. A situation where
this may happen is in case of multiple co-primary endpoints with differing treatment
effects. When the study sample size is chosen such that adequate power is assured for
the outcome with the smallest minimally clinically relevant effect size, an excessive
power may result for the endpoint with the largest treatment effect. If a single endpoint
is used, the actual treatment effect will usually be not much larger than the clinically
relevant treatment effect assumed in the sample size calculation of the study. In
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indications where treatments are already approved and on the market, the clinically
relevant effect is generally near the observed effect of the standard. Hence, in case of
indications with existing treatments a reasonable power of the blinded test is only
achieved if a new treatment shows a “jump” in efficacy, which may happen only in
exceptional cases in drug development. Consequently, the only realistic situations
where reliable information about the treatment effect can be gained from blinded data in
case of an overpowered study are in trials which are performed with common treatments
but in new populations, or in indications where no efficacious treatment exists up to
now. Especially in these situations, adequate measures should be taken to exclude the
use of blinded data for inference about the treatment effect. First of all, the use of
alternative randomisation techniques to block randomisation (see e.g. [19]) could be
considered. If block randomisation is used the block length should be chosen not too
small. Fixed small block lengths are often used to avoid imbalances in patient numbers
between the intervention groups, for example, if randomisation is stratified by centres
with small sample sizes per centre. The results of our investigations add to the known
disadvantages of this practice  20 and should be carefully weighted against its merits
before application. Secondly, details about the randomisation procedure should not be
described in the protocol but specified in a separate document that is withheld from all
persons involved in the study. Furthermore, the process of generating the allocation
sequence should be separated from the personnel that has access to the trial database.
By this, it can definitely be avoided that knowledge about the randomisation scheme is
used to derive information about the treatment effect from the blinded study data by
application of the methods described above.
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In case of a reasonable possibility of an overpowered study, the introduction of an
interim analysis that allows for early stopping in case of overwhelming efficacy might
be an option in addition to the measures mentioned above. This is a much more efficient
way of conducting the trial than trying to recover treatment effect estimates from
blinded data.
In summary, for all proposed approaches for blinded assessment of the treatment
effect it holds true what Waksman states on the corrected EM algorithm based method,
namely “it is interesting to note that the procedure can accurately and precisely estimate
the difference when either the sample size or the true difference is sufficiently large”
 10 . However, and this is the reassuring message: For combinations of sample sizes
and treatment effects which are typical in clinical trials, no reliable inference can be
made on the treatment group difference due to the bias and imprecision of the blinded
estimates.
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APPENDIX A: BLINDED MOMENT ESTIMATOR AND BLINDED F-TEST FOR
CONTINUOUS DATA AND BLOCK LENGTH 4l 
Let B denote the covariance matrix of 1, 2, 3,( , , )
T
i i i iZ Z Z Z with 1, 1, 2,i i iZ Y Y  ,
2, 2, 3,i i iZ Y Y  , 3, 3, 4,i i iZ Y Y  , i.e,
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Then 3( , )i iZ N B  and 2 1
21 1/ 2 2
3; Ti i
T
i i i BZ B Z B Z 
 

 
 
 , where 1 (1, 0, 1)
T
  ,
2 (1, 1,1)
T
  , 3 (0,1, 0)
T
 , and 23; nc denotes the chi-square distribution with 3
degrees of freedom and non-centrality parameter nc. Since 1 21Ti iB

   for all i,
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 and 22 23; ( / )4
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  , we
get with the method of moments the estimator
2 2
4, 4,
1 1
1 3 1ˆ max ( ) ,0
4 4 1
k k
T
i i i
i i
Z AZ Z Z
k k  
 
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 
  which differs from the expression
for 2ˆ given in Reference  6 on page 484.
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Analogously to block length 2 , the following test statistics for a blinded F-test can
be derived for block length 4 :
 
1
, 4 2
4, 4
1
1
3
1
1
k
T
i i
i
blind l k
i
i
Z AZ
kF
Z Z
k









, where as in
Reference  6 4, 1, 2, 3, 4,i i i i iZ Y Y Y Y    .
25
REFERENCES
1. ICH. ICH Harmonised Tripartite Guideline E9: Statistical Principles for Clinical
Trials. Statistics in Medicine 1999; 18:1905-1942. DOI: 10.1002/(SICI)1097-
0258(19990815)18:15<1903::AID-SIM188>3.0.CO;2-F.
2. Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what. The
Lancet 2002; 359:696-700. DOI:10.1016/S0140-6736(02)07816-9.
3. CHMP. Reflection paper on methodological issues in confirmatory clinical trials
planned with an adaptive design. Doc. Ref. CHMP/EWP/2459/02. London: 2007.
http://www.emea.europa.eu/pdfs/human/ewp/245902enadopted.pdf (accessed Nov.
3, 2008).
4. Fleming TR, Sharples K, McCall J, Moore A, Rodgers A, Stewart R. Maintaining
confidentiality of interim data to enhance trial integrity and credibility. Clinical
Trials 2008; 5:157-167. DOI: 10.1177/1740774508089459.
5. CPMP. Biostatistical methodology in clinical trials in applications for marketing
authorizations for medicinal products. Statistics in Medicine 1995; 14:1659-1682.
DOI: 10.1002/sim.4780141507.
6. Van der Meulen EA. Are we really that blind? Journal of Biopharmaceutical
Statistics 2005; 15:479-489. DOI: 10.1081/BIP-200056540.
7. Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally
distributed outcomes with unknown variance. Communications in Statistics –
Theory and Methods 1992; 21:2833-2853. DOI: 10.1080/03610929208830947.
26
8. Friede T, Kieser M. On the inappropriateness of an EM algorithm based procedure
for blinded sample size re-estimation. Statistics in Medicine 2002; 21:165-176.
DOI: 10.1002/sim.977
9. Friede T, Kieser M. Authors’ Reply to Letter to the Editor by Gould AL, Shih WJ.
Statistics in Medicine 2005; 24:154-156. DOI: 10.1002/sim.1894.
10. Waksman JA. Assessment of the Gould-Shih procedure for sample size re-
estimation. Pharmaceutical Statistics 2007; 6:53-65. DOI: 10.1002/pst.244.
11. Xing B, Ganju J. A method to estimate the variance of an endpoint from an on-
going blinded trial. Statistics in Medicine 2005; 24:1807-1814. DOI:
10.1002/sim.2070.
12. Ganju J, Xing B. Re-estimating the sample size of an on-going blinded trial based
on the method of randomization block sums. Statistics in Medicine 2009; 28:24-38.
DOI: 10.1002/sim.3442.
13. Hamilton, M. A rating scale for depression. Journal of Neurology, Neurosurgery,
and Psychiatry 1960; 23:56-62.
14. Montgomery SA. Clinically relevant effect sizes in depression. European
Neuropsychopharmacology 1994; 4:283-284.
15. Linde K, Mulrow CD, Berner M, Egger M. St John’s Wort for Depression
(Review). The Cochrane Collaboration: Oxford, 2005. DOI:
10.1002/14651858.CD000448.pub3.
16. Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of
acute major depression in adults: a systematic re-examination of published and
unpublished data from randomized trials. Canadian Medical Association Journal
2008; 178:296-305. DOI:10.1503/cmaj.070693.
27
17. Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of Hypericum
extract WS 5572 versus placebo in mildly to moderately depressed patients. A
randomized double-blind multicenter clinical trial. Pharmacopsychiatry 2001; 34:96-
103. DOI: 10.1055/s-2001-14280.
18. Casagrande JT, Pike MC. An improved approximate formula for calculating sample
sizes for comparing two binomial distributions. Biometrics 1978; 34:483-486.
19. Rosenberger WF, Lachin JM. Randomization in Clinical Trials: Theory and
Practice. Wiley: New York, 2002.
20. Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials:
chance, not choice. The Lancet 2002; 359:515-519. DOI:10.1016/S0140-
6736(02)07683-3.
Figure 1. Mean simulated bias of the blinded treatment effect estimates for block length
2l  in case of normally distributed data depending on the true treatment effect 
( 1  ) and the total sample size n used for estimation (solid line: blinded ML
estimator, dotted line: blinded moment estimator).
2Figure 2. Mean simulated bias of the blinded treatment effect estimates for block length
4l  in case of normally distributed data depending on the true treatment effect 
( 1  ) and the total sample size n used for estimation (solid line: blinded ML
estimator, dotted line: blinded moment estimator).
3Figure 3. Box-whisker plot of the simulated distributions of the blinded estimates 
of the absolute value of the treatment effect  in case of normally distributed data
depending on the true treatment effect  ( 1  ) and the total sample size n used for
estimation (white: blinded ML estimator, grey: blinded moment estimator; in the box-
whisker plot, bottom and top of the boxes are located at the first and third quartile,
respectively, the central horizontal line marks the median, and 5 per cent and 95 per
cent quantile are indicated by the ends of the whiskers).
4Figure 4. Ratio r of the true treatment effect  to the assumed effect * that is
required to achieve a power of 1 0.50  and 0.80 , respectively, for the blinded F-
test. The sample size is chosen such that the unblinded two-sided t-test at 05.0 has
a power of 80 per cent at the assumed treatment effect * ( =1)  .
5Figure 5. Box-whisker plot of the simulated distributions of the blinded estimates 
of the absolute value of the treatment effect  in case of binary data depending on the
true treatment effect  , the overall event rate  and the total sample size n used for
estimation (white: blinded ML estimator, grey: blinded moment estimator; in the box-
whisker plot, bottom and top of the boxes are located at the first and third quartile,
respectively, the central horizontal line marks the median, and 5 per cent and 95 per
cent quantile are indicated by the ends of the whiskers).
6Figure 6. Ratio r of the true treatment effect  to the assumed effect * that is
required to achieve a power of 1 0.50  and 0.80 , respectively, for the blinded
permutation test with overall event rates of 2.0 and 0.5. The sample size is chosen
such that the unblinded two-sided Fisher’s exact test at 05.0 has a power of 80 per
cent at the assumed treatment effect * .
